Company Encyclopedia
View More
name
Bayer AG
BAYN.DE
News
View More

Goldman Sachs Group Increases Total Voting Rights in Bayer AG to 5.41%

Goldman Sachs Group, Inc. has increased its voting rights in Bayer AG from 5.14% to 5.41%, marking a 0.27 percentage point rise. This change was reported by Bayer AG through EQS News on December 5, 2025. The information is provided by Public Technologies using AI and is not financial advice.

Reuters·
US
GS
0.00%
DE
BAYN
0.00%
Reuters·
US
GS
0.00%
DE
BAYN
0.00%

Goldman Sachs Group Increases Total Voting Rights in Bayer AG to 3.17%

Goldman Sachs Group has increased its total voting rights in Bayer AG from 4.75% to 5.14%, a rise of 0.39 percentage points.

Reuters·
US
GS
0.00%
DE
BAYN
0.00%
Reuters·
US
GS
0.00%
DE
BAYN
0.00%

Bayer Launches Phase IIa Trial of BAY 3401016 for Alport Syndrome

Bayer AG has initiated a Phase IIa clinical trial for BAY 3401016, targeting Semaphorin 3A in Alport Syndrome. The ASSESS trial is a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of BAY 3401016 in adult patients. The drug has received Fast Track and Orphan Drug Designation from the U.S. FDA. The study has just commenced, and results are not yet available.

Reuters·
DE
BAYN
0.00%
Reuters·
DE
BAYN
0.00%

Bayer: Study For Gadoquatrane In Children Meets Primary, Secondary Endpoints

BAYER AG :PEDIATRIC STUDY FOR BAYER'S INVESTIGATIONAL MRI CONTRAST AGENT GADOQUATRANE IN CHILDREN MEETS PRIMARY AND SECONDARY ENDPOINTS

Reuters·
DE
BAYN
0.00%
Reuters·
DE
BAYN
0.00%

Bayer Unveils Positive Pediatric Study Results for Low-Dose MRI Contrast Agent Gadoquatrane

Bayer AG announced positive results from the QUANTI Pediatric study on its low-dose MRI contrast agent, gadoquatrane, for children. The study showed that gadoquatrane, at a reduced gadolinium dose, has similar pharmacokinetic behavior in children as in adults. These findings were presented at the RSNA annual congress. Bayer has applied for marketing authorization in several regions, including Japan, the U.S., the EU, and China. If approved, it will be the lowest dose macrocyclic gadolinium-based contrast agent available.

Reuters·
DE
BAYN
0.00%
Reuters·
DE
BAYN
0.00%
© 2025 Longbridge｜Disclaimer